Hubbry Logo
Prostaglandin H2Prostaglandin H2Main
Open search
Prostaglandin H2
Community hub
Prostaglandin H2
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Prostaglandin H2
Prostaglandin H2
Prostaglandin H2
View on Wikipedia
from Wikipedia
Prostaglandin H2[1]
Names
Other names
PGH2, Endoperoxide H2, Prostaglandin R2
Identifiers
3D model (JSmol)
ChEBI
ChemSpider
MeSH Prostaglandin+H2
UNII
  • InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18-14-19(17)25-24-18)10-7-4-5-8-11-20(22)23/h4,7,12-13,15-19,21H,2-3,5-6,8-11,14H2,1H3,(H,22,23)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1 checkY
    Key: YIBNHAJFJUQSRA-YNNPMVKQSA-N checkY
  • InChI=1/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18-14-19(17)25-24-18)10-7-4-5-8-11-20(22)23/h4,7,12-13,15-19,21H,2-3,5-6,8-11,14H2,1H3,(H,22,23)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1
    Key: YIBNHAJFJUQSRA-YNNPMVKQBN
  • O=C(O)CCC/C=C\C[C@H]2[C@H]1OO[C@H](C1)[C@@H]2/C=C/[C@@H](O)CCCCC
Properties
C20H32O5
Molar mass 352.465 g/mol
Density 1.129 ± 0.06 g/mL
Boiling point 490 ± 40.0 °C
0.034 g/L
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Prostaglandin H2 (PGH2), or prostaglandin H2 (PGH2), is a type of prostaglandin and a precursor for many other biologically significant molecules. It is synthesized from arachidonic acid in a reaction catalyzed by a cyclooxygenase enzyme.[2] The conversion from arachidonic acid to prostaglandin H2 is a two-step process. First, COX-1 catalyzes the addition of two free oxygens to form the 1,2-dioxane bridge and a peroxide functional group to form prostaglandin G2 (PGG2).[3] Second, COX-2 reduces the peroxide functional group to a secondary alcohol, forming prostaglandin H2. Other peroxidases like hydroquinone have been observed to reduce PGG2 to PGH2.[4] PGH2 is unstable at room temperature, with a half life of 90–100 seconds,[1] so it is often converted into a different prostaglandin.

Eicosanoid synthesis – prostaglandin H2 near center

It is acted upon by:

It rearranges non-enzymatically to:

Functions of prostaglandin H2:

  • regulating the constriction and dilation of blood vessels
  • stimulating platelet aggregation
    • binds to thromboxane receptor on platelets' cell membranes to trigger platelet migration and adhesion to other platelets.[5]

Effects of aspirin on prostaglandin H2:

  • Aspirin has been hypothesized to block the conversion of arachidonic acid to prostaglandin
Figure 1: Synthetic pathways from PGH2 (the parent compound) to prostaglandins, prostacyclin and thromboxanes

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Prostaglandin H2

View on Grokipedia
from Grokipedia
Prostaglandin H₂ (PGH₂) is a mediator with the molecular formula C₂₀H₃₂O₅, acting as the pivotal endoperoxide intermediate in the of all 2-series and thromboxanes from . It features a ring fused with a 9,11-endoperoxide bridge, a 15-hydroxy group, and unsaturated side chains, making it chemically unstable under physiological conditions. PGH₂ is generated through the sequential and activities of prostaglandin endoperoxide H synthases (PGHS-1/COX-1 and PGHS-2/COX-2), which convert first to the hydroperoxy intermediate PGG₂ and then to PGH₂. As the common substrate for terminal prostanoid synthases, PGH₂ is enzymatically transformed into bioactive derivatives such as prostaglandin E₂ (PGE₂) and D₂ (PGD₂) via isomerases, prostaglandin F₂α (PGF₂α) via reductases, prostacyclin (PGI₂) by prostacyclin synthase, and thromboxane A₂ (TXA₂) by thromboxane synthase. These metabolites regulate diverse physiological processes, including and , platelet aggregation, , and contraction. Beyond its precursor role, PGH₂ exerts direct effects, such as promoting endothelium-dependent contractions and contributing to vascular tone modulation in certain tissues. Its overproduction is implicated in pathological states like and , making PGH₂ a target for non-steroidal drugs (NSAIDs) that inhibit upstream COX enzymes.

Introduction

Overview

Prostaglandin H2 (PGH2) is a cyclic endoperoxide prostaglandin derived from , acting as the central intermediate and precursor in the of other key eicosanoids, including prostaglandins PGE2, PGD2, and PGF2α, as well as (PGI2) and (TXA2). This derivation positions PGH2 at the hub of the cyclooxygenase pathway, where it is rapidly transformed by tissue-specific isomerases and synthases into these bioactive derivatives. As an unstable signaling molecule, PGH2 contributes to the modulation of through promotion of and leukocyte recruitment, influences by affecting platelet function and vascular integrity, and regulates vascular tone via balanced production of vasodilatory and vasoconstrictory products. Its transient existence ensures localized, paracrine actions within tissues, preventing widespread systemic effects. PGH2 exhibits a remarkably short of approximately 5 minutes at 37 °C and physiological (around 7.4), highlighting its chemical instability and the need for immediate enzymatic processing to generate functional eicosanoids. This ephemerality underscores PGH2's role as a pivotal, short-lived nexus in eicosanoid-mediated signaling.

Discovery and History

The foundational research on Prostaglandin H2 (PGH2) emerged from studies in the 1960s on the of , a polyunsaturated , conducted by Bengt Samuelsson and his colleagues at the . In 1965, Samuelsson's group demonstrated that serves as a direct precursor for the of prostaglandins in guinea pig tissue, establishing a key biogenetic link that laid the groundwork for identifying enzymatic intermediates in this pathway. This work built on earlier discoveries of prostaglandins in but shifted focus to their molecular origins, revealing the complexity of arachidonic acid conversion through oxidative processes. The specific identification of PGH2 as a crucial intermediate occurred in the early 1970s during detailed investigations of prostaglandin synthesis using ovine seminal vesicle microsomes. In , Mats Hamberg and Samuelsson detected and isolated an unstable endoperoxide intermediate, initially termed PGG2, from short incubations of , marking the first evidence of such a cyclic in the pathway. Building on this, in 1974, Hamberg, Jan Svensson, Toshio Wakabayashi, and Samuelsson isolated and elucidated the structures of two endoperoxides: PGG2 (with a hydroperoxy group) and PGH2 (a reduced form with a at the 15-position), confirming PGH2's role as the immediate product of the reaction. By 1975, further characterization integrated PGH2 into the full pathway, highlighting its instability ( of approximately 5 minutes) and conversion to primary prostaglandins like PGE2 and PGD2. Samuelsson's elucidation of the pathway, including PGH2's central position, earned him a share of the 1982 Nobel Prize in Physiology or Medicine, awarded jointly with and John R. Vane for their discoveries concerning prostaglandins and related biologically active substances. This recognition underscored the pathway's implications for physiological regulation, as detailed in Samuelsson's Nobel lecture. In the late and early , understanding of PGH2 evolved from viewing it merely as an unstable intermediate to recognizing it as a pivotal precursor in diversification, particularly through its transformation into thromboxanes. In 1975, Hamberg, Svensson, and Samuelsson discovered (TXA2), an even more transient derivative (half-life ~32 seconds) formed from PGH2 in human platelets, which potently induces aggregation and . Early studies further clarified PGH2's direct contributions to thromboxane synthesis via thromboxane synthase, emphasizing its role in and inflammatory responses, as explored in Samuelsson's ongoing research. Samuelsson continued his research until his death on July 5, 2024.

Chemical Structure and Properties

Molecular Formula and Structure

Prostaglandin H2 (PGH2) possesses the molecular formula C20_{20}H32_{32}O5_{5}. The compound's IUPAC name is (5Z,13E)-9α\alpha,11α\alpha-epidioxy-15SS-hydroxyprosta-5,13-dienoic acid, reflecting its prostanoic acid backbone modified by oxygenation. Alternatively, it is denoted using bicyclic nomenclature as (5Z)-7-[(1S,2R,3R,4R)-3-[(1E,3S)-3-hydroxyoct-1-enyl]-5,6-dioxabicyclo[2.2.1]heptan-2-yl]hept-5-enoic acid to emphasize the endoperoxide moiety. Structurally, PGH2 consists of a five-membered ring bearing an endoperoxide bridge between C9 and C11 in the 9α\alpha,11α\alpha configuration, which imparts inherent instability to the molecule. This ring is substituted with two side chains: the α\alpha-chain (carboxy-terminated) featuring a cis (Z) between C5 and C6, and the ω\omega-chain (alkyl-terminated) with a trans (E) between C13 and C14 and a hydroxyl group at C15 in the S configuration. The full includes chiral centers at C8 (R), C9 (S), C11 (R), C12 (R), and C15 (S), contributing to its biological specificity. In standard 2D representations, PGH2 is depicted with the cyclopentane ring at the center, the endoperoxide as a fused oxygen bridge across C9-C11, the α\alpha-chain extending upward with the carboxylic acid at the terminus, and the ω\omega-chain downward incorporating the 15-hydroxy and 13E-unsaturation.

Physical and Chemical Characteristics

Prostaglandin H2 (PGH2) possesses a molar mass of 352.47 g/mol, consistent with its molecular formula C20_{20}H32_{32}O5_{5}. It typically appears as a colorless to pale yellow oil under standard conditions. Key physical properties include a predicted density of 1.129 ± 0.06 g/cm³ and a boiling point of 490.1 ± 40.0 °C. PGH2 exhibits low solubility in , approximately 0.034 g/L, reflecting its lipophilic nature. Chemically, PGH2 is characterized by the presence of an endoperoxide moiety, which confers high instability and a propensity for spontaneous in aqueous solutions. The group has a pKa of approximately 4.5, typical for prostaglandin derivatives. Additionally, the endoperoxide functionality renders PGH2 reactive toward reducing agents, facilitating its conversion to other prostanoids. Stability studies indicate a short of approximately 3-5 minutes at 37 °C and 7.4, during which it decomposes primarily to (PGE2) and (PGD2).

Biosynthesis

Pathway from Arachidonic Acid

Prostaglandin H2 (PGH2) is synthesized through the cyclooxygenase pathway, beginning with the release of from membrane phospholipids. , a C20:4 ω-6 polyunsaturated , is liberated primarily by the action of (PLA2), which hydrolyzes phospholipids in response to cellular signals. The first committed step involves the cyclooxygenation of to form the intermediate prostaglandin G2 (PGG2). This reaction, catalyzed by the activity of prostaglandin endoperoxide H synthases, incorporates two molecules of oxygen: one at the 11-position to form a cyclic endoperoxide bridge between carbons 9 and 11, and another at the 15-position to generate a hydroperoxy group, resulting in the 15-hydroperoxy endoperoxide structure of PGG2. The second step entails the peroxidase-mediated reduction of PGG2 to PGH2. This process transfers two electrons to reduce the 15-hydroperoxy group to a 15-hydroxy group, yielding the unstable endoperoxide PGH2 while preserving the 9,11-endoperoxide. The overall reaction can be summarized as: Arachidonic acid+2 O2→PGH2\text{Arachidonic acid} + 2\, \text{O}_2 \rightarrow \text{PGH}_2 This bifunctional catalysis occurs at the active sites of the synthases. The pathway is tightly regulated by physiological stimuli. Hormones such as activate PLA2 to enhance release, thereby stimulating PGH2 production in various cell types, including fibroblasts and endothelial cells. Additionally, mechanical , as experienced by vascular endothelial cells, upregulates activity, promoting PGH2 synthesis and subsequent formation to maintain vascular .

Role of Cyclooxygenase Enzymes

Prostaglandin H2 (PGH2) is synthesized primarily through the action of enzymes, also known as prostaglandin H synthases (PGHS), which are bifunctional proteins possessing both and activities. The activity catalyzes the bis-dioxygenation of to form the hydroperoxy endoperoxide intermediate prostaglandin G2 (PGG2), while the activity subsequently reduces the hydroperoxy group at C15 of PGG2 to a , yielding PGH2. These enzymes are membrane-bound glycoproteins embedded in the and , requiring as a cofactor for function. There are two main isoforms of : COX-1 and COX-2. COX-1, encoded by the PTGS1 gene, is constitutively expressed and performs housekeeping functions, maintaining basal levels of essential for physiological processes. In contrast, COX-2, encoded by the PTGS2 gene, is inducible and upregulated in response to inflammatory stimuli such as cytokines and growth factors. A third variant, COX-3, is a splice variant of COX-1 that has been identified primarily in canine tissues and is sensitive to acetaminophen, but its functional role in biosynthesis remains less established and debated in humans. The catalytic mechanism of the cyclooxygenase activity begins with the abstraction of the pro-S hydrogen at C13 of arachidonic acid by a tyrosyl radical (Tyr-385), forming a pentadienyl radical intermediate. This is followed by the insertion of molecular oxygen: first at C11 to generate a peroxyl radical, leading to endoperoxide formation between C9 and C11, and then at C15 to produce the hydroperoxy group in PGG2. The peroxidase activity then facilitates the two-electron reduction of this hydroperoxy group to the corresponding alcohol in PGH2, utilizing electron donors such as glutathione (GSH) or phenolic compounds to regenerate the active ferric-heme state. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit activity, with aspirin acting uniquely by irreversibly acetylating a serine residue (Ser-530 in COX-1 and Ser-516 in COX-2) within the , thereby blocking substrate binding and preventing PGH2 formation. Tissue distribution of the isoforms differs markedly: COX-1 is ubiquitously expressed across most tissues, including platelets, gastrointestinal , and endothelial cells, supporting cytoprotective and hemostatic roles; COX-2 is predominantly found in macrophages, endothelial cells, and fibroblasts at sites of , contributing to amplified production during pathological conditions.

Metabolism

Enzymatic Conversions to Derivatives

Prostaglandin H2 (PGH2) serves as a central intermediate in , undergoing rapid enzymatic or reduction by specific synthases to yield bioactive derivatives. These conversions are tightly regulated and occur in distinct cellular compartments, ensuring the production of prostanoids with opposing physiological roles, such as versus . The enzymes involved, including prostaglandin E synthase (PGES), prostaglandin D synthase (PGDS), prostaglandin F synthase (PGFS), prostacyclin synthase (PTGIS), and thromboxane synthase (TBXS), catalyze stereospecific transformations of the unstable endoperoxide moiety in PGH2. Conversion to (PGE2) is mediated by PGES, which catalyzes the -dependent isomerization of PGH2 through addition of water across the 9,11-endoperoxide bridge, yielding PGE2 with a 9-keto-11α-hydroxy structure. There are three isoforms of PGES—microsomal PGES-1 (mPGES-1), mPGES-2, and cytosolic PGES (cPGES)—with mPGES-1 being inducible and linked to inflammatory responses. This reaction proceeds via a mechanism involving nucleophilic attack by on the endoperoxide, facilitating ring opening and hydration. Prostaglandin D2 (PGD2) is formed from PGH2 by PGDS through a dehydration-rehydration , rearranging the endoperoxide to produce the characteristic 9α-hydroxy-11-keto ring. Two main types exist: lipocalin-type PGDS (L-PGDS), which is glutathione-independent and predominant in the , and hematopoietic PGDS (H-PGDS), which requires and is expressed in immune cells like mast cells. The catalytic mechanism involves initial cleavage of the oxygen-oxygen bond, followed by proton transfer to form the keto group at C-11. The reduction of PGH2 to prostaglandin F2α (PGF2α) is catalyzed by PGFS, which reduces the 9,11-endoperoxide to a 9α,11α-diol structure using NADPH as a cofactor. This enzyme, often represented by aldo-keto reductase family member AKR1C3 in humans, operates in tissues such as the and , where PGF2α plays roles in reproductive processes. The mechanism entails sequential hydride transfer and , converting the to hydroxyl groups without altering the ring. Prostacyclin (PGI2) synthesis occurs via PTGIS, a enzyme that isomerizes PGH2 to a bicyclic , featuring a six-membered ring fused to the with an exocyclic . This transformation involves heterolytic cleavage of the endoperoxide and intramolecular rearrangement, preserving the side chains while forming the characteristic ω-chain linkage. PTGIS is membrane-bound and requires for activity. Thromboxane A2 (TXA2) is generated by TBXS (also known as TXAS), which rearranges PGH2 to form a six-membered oxane ring with an exocyclic epoxide, alongside minor products like 12-hydroxyheptadecatrienoic acid. As a cytochrome P450 enzyme, TBXS catalyzes this via oxygen rebound from a ferryl-oxo intermediate, leading to ring contraction and dehydration. The reaction is highly efficient, producing equimolar amounts of TXA2 and the byproduct. These synthases exhibit tissue-specific expression, contributing to localized prostanoid profiles; for instance, TBXS is predominantly expressed in platelets, favoring TXA2 production to promote aggregation, while PTGIS is enriched in vascular endothelial cells, directing PGH2 toward anti-thrombotic PGI2. Similarly, H-PGDS is prominent in hematopoietic cells for PGD2, and mPGES-1 in inflammatory sites for PGE2.

Non-Enzymatic Degradation

Prostaglandin H2 (PGH2) is highly unstable and undergoes spontaneous non-enzymatic degradation primarily through rearrangement of its cyclic endoperoxide moiety. This process involves acid-catalyzed or thermal isomerization, yielding (PGE2) as the predominant product and (PGD2) as a minor product, often in an approximate ratio of 2:1 PGE2 to PGD2. The instability arises from the strained endoperoxide bridge, which facilitates the opening and subsequent cyclization to form the characteristic five-membered ring structures of PGE2 and PGD2 without enzymatic intervention. The kinetics of this degradation are strongly influenced by environmental conditions, particularly and . At physiological temperatures of 37°C and neutral (7-8) in aqueous buffers, PGH2 exhibits a half-life of approximately 5 minutes, with decomposition accelerating under acidic conditions or elevated temperatures. Additional minor products from non-enzymatic degradation include 12-hydroxy-8,10-heptadecadienoic acid (HHT) and (MDA), formed via cleavage of the chain adjacent to the endoperoxide. These arise spontaneously from PGH2 instability and represent a parallel pathway to the products. In physiological settings, this non-enzymatic breakdown becomes relevant when downstream synthases are absent or overwhelmed, contributing to baseline production, as observed in tissues like the rat lens where PGH2 spontaneously yields PGE2, PGD2, and related compounds.

Biological Functions

Vascular Regulation

Prostaglandin H2 (PGH2) directly induces vasoconstriction by binding to thromboxane-prostanoid (TP) receptors on vascular smooth muscle cells, which triggers an increase in intracellular calcium concentration and promotes muscle contraction. This receptor activation is particularly evident in models of endothelial dysfunction, such as the spontaneously hypertensive rat (SHR) aorta, where PGH2 elicits endothelium-dependent contractions through TP receptor signaling. The potency of PGH2 as a TP agonist surpasses that of TXA2 in vascular smooth muscle, contributing to its role as a key mediator of constrictive responses. As the central precursor in prostanoid biosynthesis, PGH2 is enzymatically converted to (PGI2) by prostacyclin synthase in endothelial cells, which binds IP receptors to induce , or to (TXA2) by thromboxane synthase predominantly in platelets, amplifying via TP receptors. This bifurcation enables PGH2 to orchestrate a dynamic balance between endothelial protective effects and platelet-mediated constriction, fine-tuning vascular tone under varying physiological demands. Physiologically, PGH2 modulates local flow in response to or hypoxia, such as by supporting through prostanoid-dependent mechanisms that adjust arteriolar resistance to maintain . Experimental evidence from infusion studies in perinatal lamb models demonstrates PGH2's vasoconstrictive impact, with intravenous doses of 0.24–0.61 μg/kg producing dose-dependent elevations in pulmonary averaging 50% above baseline values. Platelet-derived TXA2 from PGH2 conversion reinforces this hemodynamic control in vascular contexts.

Platelet Aggregation

Prostaglandin H2 (PGH2) plays a pivotal role in platelet aggregation through its conversion to (TXA2) within platelets. In platelets, PGH2, formed from via cyclooxygenase-1, is rapidly transformed into TXA2 by the enzyme thromboxane synthase. TXA2 then binds to the G protein-coupled thromboxane-prostanoid (TP) receptor on the platelet surface, triggering intracellular signaling cascades that include activation of , elevation of cytosolic calcium, and activation. This receptor activation induces a conformational change in the GPIIb/IIIa integrin (αIIbβ3) on the platelet membrane through inside-out signaling, enabling the binding of fibrinogen and . The resulting cross-linking of platelets via these adhesive proteins promotes irreversible aggregation and clot formation. Seminal studies identified TXA2 as the key platelet-aggregating factor derived from PGH2 endoperoxides, confirming its potent effects on human platelet aggregation. PGH2 itself exhibits weak agonistic activity at TP receptors, directly contributing to platelet shape change and granule release, which synergizes with TXA2 to amplify the aggregatory response. This process is essential for primary at sites of vascular injury, where exposed subendothelial stimulates PGH2 production to initiate rapid formation; however, it is counterbalanced briefly by endothelial-derived (PGI2). In vivo evidence demonstrates that blockade of PGH2/TXA2 pathways significantly reduces . For instance, administration of the TXA2 Bay U3405 inhibited acute platelet-dependent in a canine model of arterial . Similarly, the TXA2 sulotroban reduced coronary in vivo by preventing platelet aggregation at the site of endothelial damage.

Inflammatory Processes

Prostaglandin H2 (PGH2) serves as a critical precursor in the biosynthesis of pro-inflammatory prostanoids, particularly (PGE2) and (PGD2), which drive key features of acute such as fever, , and . PGE2, formed from PGH2 via microsomal prostaglandin E synthase-1 (mPGES-1), sensitizes nociceptors to enhance perception and acts centrally to induce fever by resetting hypothalamic thermoregulatory centers. Similarly, PGD2 derived from PGH2 contributes to local inflammatory responses, including that supports immune cell recruitment at sites of . Beyond its role as a precursor, PGH2 directly modulates by binding to and activating the thromboxane-prostanoid (TP) receptor on immune and vascular cells, thereby promoting production and leukocyte . TP receptor stimulation by PGH2 enhances the release of pro-inflammatory s, including interleukin-6 (IL-6), from macrophages and other immune effectors, intensifying the inflammatory milieu. This activation also facilitates leukocyte to endothelial surfaces, aiding and amplifying tissue infiltration during inflammatory responses. PGH2 levels rise markedly in inflammatory contexts due to the induction of (COX-2), which catalyzes its formation from in response to signals from or tissue damage. Such upregulation occurs in macrophages and fibroblasts at inflamed sites, linking PGH2 production to the broader pro-inflammatory signaling network triggered by pathogens or injury. Studies in animal models of provide compelling evidence for PGH2's pro-inflammatory impact, where inhibition of its synthesis via COX-2 blockade or genetic disruption of downstream enzymes like mPGES-1 significantly reduces joint swelling, synovial , and behaviors. These findings underscore PGH2's essential contribution to inflammatory without affecting baseline .

Clinical Significance

Involvement in Pathophysiology

Prostaglandin H2 (PGH2), as the precursor to (TXA2), plays a critical role in cardiovascular through its promotion of platelet aggregation and . In , elevated PGH2-derived TXA2 contributes to formation on ruptured plaques, exacerbating and increasing the risk of acute events such as . This pro-thrombotic effect is mediated by TXA2 binding to its receptor on platelets and vascular cells, leading to enhanced aggregation and reduced vasodilation. Studies have shown that and in atherosclerotic lesions upregulate cyclooxygenase-1 (COX-1) activity, boosting PGH2 synthesis and TXA2 production, which perpetuates vascular damage. In inflammatory diseases, dysregulation of PGH2 metabolism contributes to chronic inflammation and tissue damage. In , PGH2 is shunted toward prostaglandin E2 (PGE2) production via COX-2 overexpression in synovial tissues, where PGE2 amplifies pain, joint swelling, and bone erosion by sensitizing nociceptors and promoting release from immune cells. Similarly, in , PGH2-derived (PGD2) drives and airway hyperresponsiveness primarily via the DP1 receptor, while its activation of the DP2 (CRTH2) receptor on and Th2 cells leads to mucus hypersecretion and inflammatory cell recruitment that sustains asthmatic exacerbations. This pathway is particularly pronounced in allergic asthma, where degranulation elevates local PGH2 levels, intensifying the inflammatory cascade. PGH2 also facilitates tumor progression in cancer, particularly through its vascular effects. In , COX-2-mediated overproduction of PGH2 leads to increased PGE2 synthesis, which stimulates endothelial and migration, thereby promoting tumor and . This angiogenic role is evidenced by correlations between COX-2 expression levels and microvessel density in colorectal tumors, where PGH2 derivatives enhance (VEGF) secretion from cancer cells. Beyond these, PGH2 imbalances are implicated in other conditions involving vascular and neuroinflammatory dysregulation. In , heightened PGH2 conversion to TXA2 in placental and maternal platelets disrupts the prostacyclin-TXA2 balance, resulting in , , and reduced uteroplacental blood flow that compromises fetal oxygenation. In , upregulated COX activity elevates PGH2 levels in the , fueling PGE2-mediated that activates , promotes amyloid-beta plaque formation, and accelerates neuronal loss. This neuroinflammatory contribution is linked to chronic glial activation, where PGH2 derivatives exacerbate synaptic dysfunction and cognitive decline.

Therapeutic Targeting

Prostaglandin H2 (PGH2) serves as a central intermediate in the pathway, making its production and downstream effects key targets for pharmacological intervention in conditions involving , , and vascular dysfunction. Non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, ibuprofen, and naproxen, inhibit (COX) enzymes, thereby reducing PGH2 synthesis from . Aspirin, in particular, irreversibly acetylates COX-1 in platelets at low doses (75-325 mg daily), suppressing PGH2-derived (TXA2) formation and providing cardioprotective antiplatelet effects, as demonstrated in large-scale trials like the Physicians' Health Study. Selective COX-2 inhibitors, such as celecoxib, preferentially block inducible PGH2 production in inflammatory settings, offering pain relief and anti-inflammatory benefits with reduced gastrointestinal side effects compared to non-selective NSAIDs, though they carry cardiovascular risks due to altered /TXA2 balance. To modulate PGH2's conversion to specific prostanoids without broadly suppressing its synthesis, thromboxane synthase inhibitors (TXSIs) have been developed, redirecting PGH2 toward anti-thrombotic and vasodilatory metabolites like (PGI2). Agents such as ozagrel and dazoxiben competitively inhibit synthase, preventing PGH2 isomerization to TXA2 and showing efficacy in preclinical models of and ischemia by enhancing PGI2 production. However, clinical translation has been limited by PGH2 accumulation, which can paradoxically activate the TP receptor and promote , as observed in early trials for prevention. Despite these challenges, TXSIs remain under investigation for niche applications, including and cancer, where TXA2 promotes tumor progression. Direct blockade of PGH2's biological actions occurs through antagonists of the thromboxane-prostanoid (TP) receptor, which binds both TXA2 and PGH2 to mediate platelet aggregation, , and . TP antagonists like ifetroban, terutroban (S18886), and ramatroban inhibit these effects, demonstrating reduced atherogenesis and improved endothelial function in animal models of and hypercholesterolemia. In clinical studies, terutroban showed promise in secondary prevention of cerebrovascular events but failed to outperform aspirin in phase III trials due to similar efficacy profiles. Emerging TP antagonists, such as NTP42, are being explored for pulmonary arterial and right heart , where they preserve cardiac function and inhibit remodeling by counteracting PGH2/TP-mediated . These agents offer a dual benefit over COX inhibitors by avoiding disruption of gastroprotective prostaglandins. Therapeutic strategies targeting PGH2 also extend to downstream synthases for disease-specific modulation, such as microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors, which prevent PGH2 conversion to pro-inflammatory PGE2 in cancer and neurodegeneration. Earlier compounds like LY3023703 entered clinical trials but were halted due to concerns; more recent candidates, such as vipoglanstat, are under investigation in Phase 2 trials for and as of 2024, showing potential superior tolerability over COX-2 inhibitors. Overall, PGH2 targeting balances against off-target effects, with ongoing prioritizing combination therapies—such as TP antagonists with low-dose aspirin—to optimize outcomes in cardiovascular and inflammatory disorders.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/445049
  2. https://www.hmdb.ca/metabolites/HMDB0001381
  3. https://pubmed.ncbi.nlm.nih.gov/11121412/
  4. https://pubmed.ncbi.nlm.nih.gov/1905023/
  5. https://pubmed.ncbi.nlm.nih.gov/8349035/
  6. https://www.sciencedirect.com/science/article/pii/B978012800254400009X
  7. https://www.sciencedirect.com/science/article/pii/B9780080468846008216
  8. https://www.sciencedirect.com/science/article/pii/B9781437716795000375
  9. https://www.sciencedirect.com/science/article/pii/B0122267656000566
  10. https://www.pnas.org/doi/10.1073/pnas.71.2.345
  11. https://www.nobelprize.org/prizes/medicine/1982/samuelsson/facts/
  12. https://www.nobelprize.org/prizes/medicine/1982/press-release/
  13. https://www.nasonline.org/wp-content/uploads/2024/12/Samuelsson-Bengt.pdf
  14. https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483
  15. https://www.medchemexpress.com/prostaglandin-h2.html
  16. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7291001.htm
  17. https://np-mrd.org/natural_products/NP0334676
  18. https://www.sciencedirect.com/science/article/pii/S2773176625000112
  19. https://www.pnas.org/doi/pdf/10.1073/pnas.71.2.345
  20. https://pubchem.ncbi.nlm.nih.gov/compound/Arachidonic-Acid
  21. https://www.nature.com/articles/s41392-020-00443-w
  22. https://www.jbc.org/article/S0021-9258(19)65286-5/fulltext
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC3481335/
  24. https://www.pnas.org/doi/10.1073/pnas.84.18.6374
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC5402016/
  26. https://pubs.acs.org/doi/10.1021/acs.chemrev.0c00215
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC2674713/
  28. https://www.pnas.org/doi/10.1073/pnas.162468699
  29. https://www.beilstein-journals.org/bjoc/articles/18/71
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC6355089/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC4688592/
  32. https://pubmed.ncbi.nlm.nih.gov/12432931/
  33. https://www.pnas.org/doi/10.1073/pnas.1218504110
  34. https://pubmed.ncbi.nlm.nih.gov/10668396/
  35. https://www.ncbi.nlm.nih.gov/books/NBK6621/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC3095374/
  37. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2012.00098/full
  38. https://pubmed.ncbi.nlm.nih.gov/2491846/
  39. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/prostacyclin-synthase
  40. https://febs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1432-1033.1987.tb13646.x
  41. https://www.sciencedirect.com/topics/medicine-and-dentistry/thromboxane-synthase-inhibitor
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC4175445/
  43. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2021.718002/full
  44. https://www.nature.com/articles/pr1986127.pdf
  45. https://pubmed.ncbi.nlm.nih.gov/3472900/
  46. https://www.sciencedirect.com/science/article/pii/B978012394383500014X
  47. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2011.01276.x
  48. https://www.sciencedirect.com/science/article/pii/B9780120884889500267
  49. https://pubmed.ncbi.nlm.nih.gov/3714368/
  50. https://pubmed.ncbi.nlm.nih.gov/2948839/
  51. https://www.ncbi.nlm.nih.gov/books/NBK539817/
  52. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1297263/
  53. https://www.pnas.org/doi/pdf/10.1073/pnas.72.8.2994
  54. https://www.ahajournals.org/doi/pdf/10.1161/01.cir.72.6.1202
  55. https://pubmed.ncbi.nlm.nih.gov/8115994/
  56. https://pubmed.ncbi.nlm.nih.gov/2624600/
  57. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/prostaglandin-h2
  58. https://pubmed.ncbi.nlm.nih.gov/12835414/
  59. https://www.sciencedirect.com/topics/neuroscience/prostaglandin-h2
  60. https://pubmed.ncbi.nlm.nih.gov/22206755/
  61. https://www.sciencedirect.com/science/article/pii/S1538783622038594
  62. https://www.nature.com/articles/s41598-017-09528-z
  63. https://www.sciencedirect.com/science/article/pii/S0006291X13011467
  64. https://pubmed.ncbi.nlm.nih.gov/15314505/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC2882156/
  66. https://www.ahajournals.org/doi/10.1161/ATVBAHA.124.320744
  67. https://www.jthjournal.org/article/S1538-7836(22)03859-4/pdf
  68. https://pubmed.ncbi.nlm.nih.gov/12208866/
  69. https://publications.ersnet.org/content/erj/45/4/1108
  70. https://pubmed.ncbi.nlm.nih.gov/7789486/
  71. https://www.sciencedirect.com/science/article/pii/S0092867400814336
  72. https://www.gastrojournal.org/article/S0016-5085(01)96357-7/fulltext
  73. https://www.ajog.org/article/S0002-9378(85)80223-4/fulltext
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC5384338/
  75. https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2022.769347/full
  76. https://pubmed.ncbi.nlm.nih.gov/24353037/
  77. https://www.sciencedirect.com/science/article/pii/S088985610900006X
  78. https://pubmed.ncbi.nlm.nih.gov/22918735/
  79. https://jpet.aspetjournals.org/article/S0022-3565%2825%2912210-6/fulltext
  80. https://www.ahajournals.org/doi/10.1161/circulationaha.105.581892
  81. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1063967/full
  82. https://www.ahajournals.org/doi/10.1161/JAHA.118.011902
  83. https://pubmed.ncbi.nlm.nih.gov/25961169/
  84. https://www.sciencedirect.com/science/article/pii/S1878747923001745
  85. https://academic.oup.com/rheumatology/article/64/2/704/7593822
Add your contribution
Related Hubs
User Avatar
No comments yet.